MAPK8 and renal cell carcinoma: Additionally, the specific inhibitors of TAK1 and JNK both dose-dependently provoked a reduction of AP-1 activity, confirming that AP-1 acts as downstream of TAK1, and JNK in RCC cells (Figure 6A).